Sex differences in CSF biomarkers vary by Alzheimer disease stage and APOE ε4 genotype.
Rosha Babapour MofradBetty M TijmsPhilip ScheltensFrederik BarkhofWiesje Maria van der FlierSietske A M SikkesCharlotte E TeunissenPublished in: Neurology (2020)
Within APOE ε4 carriers, sex differences in CSF p-Tau are more evident in early disease stages, whereas for APOE ε4 noncarriers, sex differences are more evident in advanced disease stages. These findings suggest that the effect of APOE ε4 on sex differences in CSF biomarkers depends on disease stage in AD.